The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRtw Biotech Regulatory News (RTW)

Share Price Information for Rtw Biotech (RTW)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.38
Bid: 1.36
Ask: 1.38
Change: 0.015 (1.10%)
Spread: 0.02 (1.471%)
Open: 1.36
High: 1.38
Low: 1.35
Prev. Close: 1.365
RTW Live PriceLast checked at -
RTW Venture is an Investment Trust

To achieve positive absolute performance and superior long-term capital appreciation, with a focus on forming, building, and supporting world-class life sciences, biopharmaceutical and medical technology companies.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Edison issues flash on RTW Biotech Opportunities (RTWBIO): Significant acquisition of Arix Bioscience’s assets

1 Nov 2023 10:51

Edison Investment Research Limited Edison issues flash on RTW Biotech Opportunities (RTWBIO): Significant acquisition of Arix Bioscience’s assets 01-Nov-2023 / 10:51 GMT/BST The issuer is solely responsible for the content of this announcement.


 

London, UK, 1 November 2023

 

Edison issues flash on RTW Biotech Opportunities (RTWBIO): Significant acquisition of Arix Bioscience’s assets

On 1 November 2023, RTW Biotech Opportunities (RTWBIO), a full life cycle biotech investor, announced what it considers to be a transformational deal. It plans to acquire the assets of UK-listed Arix Bioscience in an all-share transaction, which on a pro-forma basis would increase RTWBIO’s NAV by c $550m (c 63%). The deal brings the prospects of increased liquidity in RTWBIO’s shares and a more efficient cost base, and potential for a higher RTWBIO valuation. Arix’s shareholders would receive new RTWBIO shares at an implied c 46% premium to the level before Arix announced a strategic review. Meanwhile, RTWBIO’s management team anticipates that the deal would be single-digit accretive to the company’s NAV per share at completion.

During 2022 and so far in 2023, RTWBIO has made nine new investments and had seven successful IPOs or exits of portfolio companies. The acquisition would bring c $128m of Arix’s liquid assets, of which c $60m is expected to be in cash following completion of the scheme and the cost of the deal. RTWBIO intends to invest this capital in both public and private assets and can deploy cash quickly via investment in its ‘other public’ portfolio, which is made up of listed companies held by other RTW funds, to minimise cash drag. It can also deploy capital through its royalty and structured finance strategy, which provides an income stream with returns that are uncorrelated with equity returns and stock market volatility.Click here to view the full report.All reports published by Edison are available to download free of charge from its website

www.edisongroup.com

About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached – across institutions, family offices, wealth managers and retail investors – Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.

Having been the first company in-market 17 years ago, Edison has more than 100 employees and covers every economic sector. Headquartered in London, Edison also has offices in New York, Sydney and Wellington.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

Mel Jenner +44 (0)20 3077 5700 investmenttrusts@edisongroup.com

Learn more at www.edisongroup.com and connect with Edison on:

LinkedIn www.linkedin.com/company/edison-group-/

Twitter  www.twitter.com/Edison_Inv_Res

YouTube www.youtube.com/edisonitv


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

1762757 01-Nov-2023 

corporate announcement transmitted by EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
18th Jan 20247:00 amRNSTransaction in Own Shares
15th Jan 20247:00 amRNSMonthly Valuation Update, December Factsheet
10th Jan 20247:00 amRNSTransaction in Own Shares
8th Jan 20249:00 amRNSInvestment Update
5th Jan 20241:00 pmRNSPublication of a Prospectus
2nd Jan 20247:00 amRNSTotal Voting Rights
14th Dec 20237:00 amRNSMonthly Valuation Update, November Factsheet
6th Dec 20237:00 amRNSTransaction in Own Shares
1st Dec 20237:01 amRNSTotal Voting Rights
1st Dec 20237:00 amRNSTransaction in Own Shares
13th Nov 20237:00 amRNSPortfolio Company Update: CARGO Therapeutics, Inc
13th Nov 20237:00 amRNSTransaction in Own Shares
13th Nov 20237:00 amRNSMonthly Valuation Update, October Factsheet
9th Nov 20237:00 amRNSTransaction in Own Shares
8th Nov 20237:00 amRNSTransaction in Own Shares
1st Nov 202310:51 amEQSEdison issues flash on RTW Biotech Opportunities (RTWBIO): Significant acquisition of Arix Bioscience’s assets
1st Nov 20237:06 amRNSRTW Biotech to acquire Arix Bioscience's assets
1st Nov 20237:05 amRNSTotal Voting Rights
16th Oct 20237:00 amRNSTransaction in Own Shares
13th Oct 20237:00 amRNSMonthly Valuation Update, Sep Factsheet, Q3 Letter
3rd Oct 20234:00 pmRNSDirector Declaration
2nd Oct 20237:00 amRNSTotal Voting Rights
18th Sep 20237:00 amRNSTransaction in Own Shares
15th Sep 20237:00 amRNSMonthly Valuation Update & August Factsheet
14th Sep 20237:00 amRNSUpdate on Largest Core Portfolio Position
13th Sep 20237:00 amRNSHalf-year Report
6th Sep 20237:00 amRNSTransaction in Own Shares
4th Sep 202311:00 amRNSAdditional Investment in Portfolio Company
14th Aug 20237:00 amRNSMonthly Valuation Update & July Factsheet
4th Aug 20237:30 amRNSEdison issues update on RTW Venture Fund (RTW)
1st Aug 202312:30 pmRNSTotal Voting Rights
21st Jul 20237:00 amRNSTransaction in Own Shares
17th Jul 20237:00 amRNSPortfolio Company Update: Apogee Therapeutics IPO
17th Jul 20237:00 amRNSMonthly Valuation Update, Factsheet & Q2 Letter
5th Jul 20237:00 amRNSCapital Allocation Plans from Prometheus Sale
30th Jun 202310:00 amRNSPortfolio Company Update: Tourmaline Bio
27th Jun 20237:00 amRNSChange of Name
21st Jun 20234:22 pmRNSResult of AGM
14th Jun 20237:00 amRNSMonthly Valuation Update & Factsheet
1st Jun 20237:00 amRNSNotice of AGM
12th May 20237:00 amRNSMonthly Valuation Update & Factsheet
9th May 20237:00 amRNSPortfolio Company Update: Acelyrin IPO
2nd May 20237:00 amRNSAnnual Financial Report
26th Apr 20237:00 amRNSNew Investment in Abdera Therapeutics
24th Apr 20232:39 pmRNSMarch Factsheet & First Quarter Letter
17th Apr 20237:00 amRNSPortfolio Company Update: Prometheus Biosciences
17th Apr 20237:00 amRNSMonthly Valuation Update
6th Apr 202312:00 pmRNSAppointment of Numis as Joint Broker
31st Mar 20235:20 pmRNSDirector/PDMR Shareholding
31st Mar 20237:00 amRNSAnnual Financial Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.